317 related articles for article (PubMed ID: 33992207)
1. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
3. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Rawoot A; Little F; Heckmann JM
S Afr Med J; 2006 Dec; 96(12):1249-51. PubMed ID: 17252153
[No Abstract] [Full Text] [Related]
4. [Myasthenia gravis. Opportunistic cytomegalovirus infection after long-term azathioprine therapy].
Eisensehr I; Büttner U; Witt TN; von Appen K; Spuler S
Nervenarzt; 1999 Oct; 70(10):924-6. PubMed ID: 10554786
[TBL] [Abstract][Full Text] [Related]
5. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2014 Mar; 21(3):454-8. PubMed ID: 24330255
[TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis.
Nath UK; Bhattacharyya D; Chattopadhya D; Dhingra G; Azad S; Mohanty A
Drug Discov Ther; 2021 Mar; 15(1):48-50. PubMed ID: 33612571
[TBL] [Abstract][Full Text] [Related]
7. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis?
Herrlinger U; Weller M; Dichgans J; Melms A
Ann Neurol; 2000 May; 47(5):682-3. PubMed ID: 10805346
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
Palace J; Newsom-Davis J; Lecky B
Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive agents for myasthenia gravis.
Hart IK; Sathasivam S; Sharshar T
Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
[TBL] [Abstract][Full Text] [Related]
11. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
McGurgan IJ; McGuigan C
Brain Behav; 2015 Oct; 5(10):e00396. PubMed ID: 26516615
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.
Hohlfeld R; Michels M; Heininger K; Besinger U; Toyka KV
Neurology; 1988 Feb; 38(2):258-61. PubMed ID: 3340289
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate in generalized myasthenia gravis: a systematic review.
Prado MB; Adiao KJB
Acta Neurol Belg; 2023 Oct; 123(5):1679-1691. PubMed ID: 36967437
[TBL] [Abstract][Full Text] [Related]
14. Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients.
Rozsa C; Lovas G; Fornadi L; Szabo G; Komoly S
Eur J Neurol; 2006 Sep; 13(9):947-52. PubMed ID: 16930359
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment options for ocular myasthenia gravis.
Antonio-Santos AA; Eggenberger ER
Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
17. [Eruptive melanocytic nevi during azathioprine therapy in myasthenia gravis].
Braun SA; Helbig D; Frank J; Hanneken S
Hautarzt; 2012 Oct; 63(10):756-9. PubMed ID: 23008007
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
Cosi V; Lombardi M; Erbetta A; Piccolo G
Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
[TBL] [Abstract][Full Text] [Related]
20. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]